secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2024-01-29T23:59:59+00:00
Accession:  0001193805-24-000103
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos Therapeutics approves 1-for-15 reverse stock split effective Jan 31, 2024
--------------------------------------------------------------------------------

- Reverse split ratio of 1-for-15 approved by Board on Jan 29, 2024; effective Jan 31 at 5:00 PM ET.
- Every 15 pre-split shares combine into 1 post-split share; trading begins on split-adjusted basis Feb 1 under same symbol TCRT with new CUSIP.
- Stockholders authorized split ratio range (1-for-5 to 1-for-15) at June 2023 annual meeting; Board selected 1-for-15 on Jan 12, 2024.
- Equiniti Trust Company appointed as exchange agent for the reverse split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119380524000103/0001193805-24-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119380524000103/e619210_8k-at.htm
  HTML page:      https://secwatch.observer/filing/0001193805-24-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer